Difficulty: Medium
Average Score: 69%
Practice
Which of the following is the systemic treatment of choice for female hirsutism?
Correct answer
D
Rationale
Hirsutism involves excess androgen-driven hair growth. Tamoxifen, an estrogen modulator, treats breast cancer, not hirsutism. Ethinylestradiol reduces androgens via SHBG increase, but alone isn't optimal. Norethisterone, a progestin, may worsen hirsutism. Finasteride blocks 5-alpha-reductase, reducing DHT, but cyproterone, an anti-androgen, directly inhibits androgen receptors and gonadotropin release, the systemic choice for hirsutism (e.g., in PCOS). Its potency targets the root cause, offering effective hair reduction.